June 13, 2007 09:58 ET

Bird Flu Complacency Could Be Our Biggest Threat Creating New Technology to Counter Avian Influenza

SCOTTSDALE, AZ--(Marketwire - June 13, 2007) - (OTCBB: EFSF) -- For some, the threat of bird flu is most likely to occur in a sci-fi movie. But scientists and researchers say this "pandemic fatigue" Americans have when it comes to bird flu is dangerous, especially without a plan for the future.

According to a new survey published in the British Journal Archives of Disease in Childhood (June 2007), doctors are becoming more complacent about the threat of a bird flu pandemic. However, the spread of avian influenza A (H5N1) in 59 countries over the past four years has brought the world closer to another pandemic than at any other time since 1968.

While there have been no human cases of H5N1 in the United States, scientists worldwide are concerned that H5N1, which can pass from poultry to humans, may mutate enabling it to transmit from human to human and start an infulenza pandemic.

With no commercially available vaccine to protect humans from bird flu, health technology company, (OTCBB: EFSF) is in the research and production phases of developing a unique delivery system for its clinically studied Citroxin, which has already been proven to be very effective in treating the surrogate H9N2 strain of the bird flu virus.

Citroxin is a natural germicidal cleaner that has a 100 percent kill rate on major bacteria including staph, salmonella, strep, E. coli, listeria and pseudomonas. Citroxin can be sprayed on bird cages and hen houses without causing harm to animals or humans. The new delivery system is developing will enable Citroxin to be absorbed into the blood stream to prevent bird flu in humans.

The company is currently testing Citroxin at Thailand's largest private biotechnology company, Innova Biotechnology. The tests are particularly significant since the Citroxin is being tested on the actual H5N1 strain of the bird flu virus and not on the surrogate H9N2 strain that most domestic laboratories use for bird flu testing. Results are expected to reaffirm already positive conclusions from U.S. testing of Citroxin as an effective anti-viral prophylaxis for bird flu.

Some analysts predict that Citroxin could become the leading anti-viral prophylaxis for the bird flu (H5N1). is an early-stage holding company that focuses on innovative product development and technologies for improving health conditions worldwide. For more information visit:

Contact Information

  • Media Contact:
    Amy Summers
    727-848-1618 ext. 202
    Email Contact
    Pitch Inc.